MX2022016407A - Anticuerpo biespecifico y los usos del mismo. - Google Patents

Anticuerpo biespecifico y los usos del mismo.

Info

Publication number: MX2022016407A
Authority: MX; Mexico
Prior art keywords: bispecific antibody; targeting; antigen binding; binding domain; human
Prior art date: 2020-06-30

Application number

MX2022016407A

Other languages

English (en)

Spanish (es)

Inventor

Lei Shi

Fei Chen

Yun He

Xiaodong Wu

Yiping Rong

Chen Zhong

Xiaocheng Lv

Jinli Xie

Bing Huang

Fangfang Du

Jianxun Zhao

Original Assignee

Harbour Biomed Us Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-06-30

Filing date

2021-06-29

Publication date

2023-04-05

2021-06-29 Application filed by Harbour Biomed Us Inc filed Critical Harbour Biomed Us Inc

2023-04-05 Publication of MX2022016407A publication Critical patent/MX2022016407A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MX2022016407A 2020-06-30 2021-06-29 Anticuerpo biespecifico y los usos del mismo. MX2022016407A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN202010618149		2020-06-30
PCT/CN2021/103058 WO2022002036A1 (fr)	2020-06-30	2021-06-29	Anticorps bispécifique et son utilisation

Publications (1)

Publication Number	Publication Date
MX2022016407A true MX2022016407A (es)	2023-04-05

Family

ID=79317488

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2022016407A MX2022016407A (es)	2020-06-30	2021-06-29	Anticuerpo biespecifico y los usos del mismo.

Country Status (13)

Country	Link
US (1)	US20230235090A1 (fr)
EP (1)	EP4155318A4 (fr)
JP (1)	JP7728595B2 (fr)
KR (1)	KR20230015957A (fr)
CN (1)	CN114667296B (fr)
AU (1)	AU2021301921B2 (fr)
BR (1)	BR112022026114A2 (fr)
CA (1)	CA3183389A1 (fr)
IL (1)	IL299232A (fr)
MX (1)	MX2022016407A (fr)
TW (1)	TWI815136B (fr)
WO (1)	WO2022002036A1 (fr)
ZA (1)	ZA202213707B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP7620780B2 (ja) *	2020-06-30	2025-01-24	ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド	Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
TWI833244B (zh) *	2021-06-18	2024-02-21	大陸商和鉑醫藥（上海）有限責任公司	一種雙抗組合及其應用
EP4389768A4 (fr) *	2021-08-18	2025-06-25	Harbour Biomed (Shanghai) Co., Ltd	Anticorps anti-b7-h4, son procédé de préparation et son utilisation
CN115368465B (zh) *	2022-07-19	2026-02-24	合肥天港免疫药物有限公司	双特异性抗体及其应用
WO2025211874A1 (fr) *	2024-04-04	2025-10-09	주식회사 크로스포인트테라퓨틱스	Anticorps bispécifique contenant un variant fc d'anticorps humain et son utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CL2008003526A1 (es) *	2007-11-30	2010-01-11	Medarex Inc	Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
GB0905023D0 (en)	2009-03-24	2009-05-06	Univ Erasmus Medical Ct	Binding molecules
US20140377253A1 (en) *	2013-03-15	2014-12-25	Abbvie Biotherapeutics Inc.	Fc variants
WO2016040724A1 (fr) *	2014-09-12	2016-03-17	Genentech, Inc.	Anticorps anti-b7-h4 et immunoconjugués
IL293435B1 (en) *	2015-06-15	2026-04-01	Numab Therapeutics AG	Heterodimeric multispecific antibody format
AU2016304794B2 (en) *	2015-08-07	2021-07-15	ALX Oncology Inc.	Constructs having a SIRP-alpha domain or variant thereof
US20190048094A1 (en) *	2016-02-24	2019-02-14	Oncomed Pharmaceuticals, Inc.	Redirecting immune responses
BR112018074453A2 (pt) *	2016-05-27	2019-03-19	Abbvie Biotherapeutics Inc.	proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
CN109563503B (zh) *	2016-07-26	2023-09-29	静冈县	抗b7-h4抗体
JP7784795B2 (ja) *	2016-11-15	2025-12-12	ジェネンテック，インコーポレイテッド	抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
EP3612567B1 (fr) *	2017-04-19	2024-09-11	Bluefin Biomedicine, Inc.	Anticorps anti-vtcn1 et conjugués anticorps-médicament
US11306144B2 (en) *	2017-08-25	2022-04-19	Five Prime Therapeutics, Inc.	B7-H4 antibodies and methods of use thereof
JP7337099B2 (ja) *	2018-05-25	2023-09-01	アレクトルエルエルシー	抗ｓｉｒｐａ抗体およびその使用法
JP2022508529A (ja) *	2018-09-29	2022-01-19	上海博槿生物科技有限公司	二重標的抗原結合分子
CN113286825B (zh) *	2018-11-30	2024-06-18	爱必乐生物公司	抗pd-l1/抗4-1bb双特异性抗体及其用途
WO2022002009A1 (fr) *	2020-06-30	2022-01-06	和铂医药(上海)有限责任公司	Anticorps ciblant ox40, son procédé de préparation et son utilisation
JP7620780B2 (ja) *	2020-06-30	2025-01-24	ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド	Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質

2021
- 2021-06-29 US US18/002,499 patent/US20230235090A1/en active Pending
- 2021-06-29 EP EP21832260.0A patent/EP4155318A4/fr active Pending
- 2021-06-29 CN CN202180005437.2A patent/CN114667296B/zh active Active
- 2021-06-29 JP JP2022579106A patent/JP7728595B2/ja active Active
- 2021-06-29 BR BR112022026114A patent/BR112022026114A2/pt unknown
- 2021-06-29 AU AU2021301921A patent/AU2021301921B2/en active Active
- 2021-06-29 KR KR1020227044792A patent/KR20230015957A/ko active Pending
- 2021-06-29 IL IL299232A patent/IL299232A/en unknown
- 2021-06-29 CA CA3183389A patent/CA3183389A1/fr active Pending
- 2021-06-29 WO PCT/CN2021/103058 patent/WO2022002036A1/fr not_active Ceased
- 2021-06-29 TW TW110123893A patent/TWI815136B/zh active
- 2021-06-29 MX MX2022016407A patent/MX2022016407A/es unknown
2022
- 2022-12-19 ZA ZA2022/13707A patent/ZA202213707B/en unknown

Also Published As

Publication number	Publication date
EP4155318A4 (fr)	2024-06-05
CA3183389A1 (fr)	2022-01-06
JP7728595B2 (ja)	2025-08-25
WO2022002036A1 (fr)	2022-01-06
EP4155318A1 (fr)	2023-03-29
KR20230015957A (ko)	2023-01-31
ZA202213707B (en)	2024-04-24
CN114667296B (zh)	2023-03-24
CN114667296A (zh)	2022-06-24
AU2021301921A1 (en)	2023-02-02
BR112022026114A2 (pt)	2023-01-17
TWI815136B (zh)	2023-09-11
IL299232A (en)	2023-02-01
JP2023530766A (ja)	2023-07-19
US20230235090A1 (en)	2023-07-27
TW202202529A (zh)	2022-01-16
AU2021301921B2 (en)	2025-02-20

Publication	Publication Date	Title
ZA202213707B (en)	2024-04-24	Bispecific antibody and use thereof
PH12020551689A1 (en)	2021-07-19	Her2-targeting antigen binding molecules comprising 4-1bbl
MX2021015888A (es)	2022-03-22	Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2021009274A (es)	2021-08-24	Moleculas de union a multiples dominios.
PH12019501440A1 (en)	2020-02-10	Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
WO2022031884A3 (fr)	2022-03-24	Molécules de liaison à il2rg et procédés d'utilisation
PH12022552318A1 (en)	2024-01-08	Bispecific antigen binding molecules targeting ox40 and fap
EP4516809A3 (fr)	2025-09-03	Anticorps bispécifiques se liant spécifiquement à pd1 et lag3
MY199140A (en)	2023-10-17	Bifunctional proteins combining checkpoint blockade for targeted therapy
WO2022032006A3 (fr)	2022-03-10	Molécules de liaison à l'il2rb et leurs procédés d'utilisation
MX2013007392A (es)	2013-11-01	Anticuerpo modificado con vida media mejorada.
MX2022001942A (es)	2022-07-27	Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
MY189159A (en)	2022-01-29	Multispecific antigen-binding molecules and uses thereof
MXPA06002890A (es)	2006-06-05	Anticuerpo antiglipicano 3.
MX2018010776A (es)	2020-09-02	Moleculas de union de antigeno multiespecificas y usos de las mismas.
AU2018338322A1 (en)	2020-04-09	A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2023008000A (es)	2023-07-13	Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.
WO2020247929A8 (fr)	2021-07-22	Anticorps anti-cd3 à haute affinité et leurs méthodes de génération et d'utilisation
WO2022031710A3 (fr)	2022-03-31	Agents de liaison multispécifiques et leurs utilisations
MX2024002013A (es)	2024-03-08	Anticuerpos biespecificos anti-b7-h4/anti-4-1bb y usos de los mismos.
MX2024015391A (es)	2025-02-10	Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico
MX2022007855A (es)	2022-09-23	Anticuerpos hvem anti-humano (tnfrsf14) y usos de los mismos.
WO2019183093A8 (fr)	2020-06-11	Anticorps monoclonaux neutralisants à haute affinité envers un ligand de mort programmée 1 (pd-l1) et leurs utilisations
EP4495142A3 (fr)	2025-05-07	Construction bispécifique de liaison à un antigène
WO2022132929A3 (fr)	2022-09-01	Molécules d'anticorps multispécifiques et leurs utilisations